Comparing Apples to Oranges: A comparison on Efficacy data for monoclonal antibodies and cholinesterase inhibitors for treatment of Alzheimer’s Disease from FDA Medical and Statistical Reports

All drugs showed a statistically significant difference ADAS-Cog scores relative to placebo. However, mAbs are tested and approved for Mild Cognitive Impairment (MCI) or mild dementia. On the other hand, AChEIs were tested and approved for moderate to severe AD. Since these studies employed different versions of the ADAS-Cog scale (e.g., ADAS-Cog 11 vs. ADAS-Cog 13), making direct comparisons of efficacy more difficult. Additional research is needed to fully assess the efficacy of these newer therapies compared to placebo.